This revealed that a SETD2 deleterious mutation was associated with a more inflamed tumor microenvironment in patients with renal cell carcinoma (Figure S4A), colorectal adenocarcinoma (Figure S4B), and endometrial carcinoma (Figure S4C). Here, SETD2 is linked to endometrial carcinoma.